Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 531
Filtrar
1.
Am J Psychiatry ; 178(5): 424-436, 2021 05 01.
Artigo em Inglês | MEDLINE | ID: mdl-33596679

RESUMO

OBJECTIVE: This study compared relapse prevention and acceptability of long-acting injectable (LAI) antipsychotics in the maintenance treatment of adults with nonaffective psychoses. METHODS: The authors searched MEDLINE, Embase, PsycINFO, CINAHL, CENTRAL, and online registers for randomized controlled trials published until June 2020. Relative risks and standardized mean differences were pooled using random-effects pairwise and network meta-analysis. The primary outcomes were relapse rate and all-cause discontinuation ("acceptability"). The quality of included studies was rated with the Cochrane Risk of Bias tool, and the certainty of pooled estimates was measured with GRADE (Grading of Recommendations Assessment, Development, and Evaluation). RESULTS: Of 86 eligible trials, 78 (N=11,505) were included in the meta-analysis. Regarding relapse prevention, most of the 12 LAIs included outperformed placebo. The largest point estimates and best rankings of LAIs compared with placebo were found for paliperidone (3-month formulation) and aripiprazole. Moderate to high GRADE certainty for superior relapse prevention compared with placebo was also found for (in descending ranking order) risperidone, pipothiazine, olanzapine, and paliperidone (1-month formulation). In head-to-head comparisons of LAIs, only haloperidol was inferior to aripiprazole, fluphenazine, and paliperidone. For acceptability, most LAIs outperformed placebo, with moderate to high GRADE certainty for (in descending ranking order) zuclopenthixol, aripiprazole, paliperidone (3-month formulation), olanzapine, flupenthixol, fluphenazine, and paliperidone (1-month formulation). In head-to-head comparisons, only LAI aripiprazole had superior acceptability to other LAIs (bromperidol, fluphenazine, paliperidone [1-month formulation], pipothiazine, and risperidone). CONCLUSIONS: LAI formulations of paliperidone (3-month formulation), aripiprazole, olanzapine, and paliperidone (1-month formulation) showed the highest effect sizes and certainty of evidence for both relapse prevention and acceptability. Results from this network meta-analysis should inform frontline clinicians and guidelines.


Assuntos
Antipsicóticos/administração & dosagem , Aceitação pelo Paciente de Cuidados de Saúde , Transtornos Psicóticos/tratamento farmacológico , Esquizofrenia/tratamento farmacológico , Aripiprazol/administração & dosagem , Clopentixol/administração & dosagem , Preparações de Ação Retardada , Flupentixol/administração & dosagem , Flufenazina/administração & dosagem , Haloperidol/administração & dosagem , Humanos , Injeções Intramusculares , Metanálise em Rede , Olanzapina/administração & dosagem , Palmitato de Paliperidona/administração & dosagem , Fenotiazinas/administração & dosagem , Risperidona/administração & dosagem , Prevenção Secundária
2.
Appl Microbiol Biotechnol ; 103(16): 6701-6709, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31201451

RESUMO

Candida albicans causes a high mortality rate in immunocompromised individuals, but the increased drug resistance challenges the current antifungal therapeutics. Fluphenazine (FPZ), a commonly used antipsychotic medication, can induce the expression of drug efflux pumps in C. albicans and, thus, may interfere with the therapeutic efficacy of antifungals, such as fluconazole (FLC) and amphotericin B (AmB). Here, we investigated the combined effects of FLC/FPZ and AmB/FPZ against C. albicans in vitro and in a systemic candidiasis mouse model. The antifungal activity of FLC was significantly reduced when supplemented with FPZ. The inhibitory effects of FLC on the expression of the Candida virulence-related genes ALS3 and HWP1 were antagonized by FPZ. However, FPZ enhanced the susceptibility of C. albicans to AmB and further downregulated the expression of ALS3 and HWP1 in a synergistic manner with AmB. FPZ also enhanced the gene expression of ERG11, a key gene of the ergosterol biosynthesis pathway that has been associated with the activities of both FLC and AmB. In our mammalian infection model, mice treated with FLC/FPZ showed notably poor living status and increased fungal burden in their kidneys and brains compared with those treated with FLC alone. Conversely, the combined application of AmB/FPZ significantly improved the survival rate, attenuated the weight loss and reduced the organ fungal burdens of the infected mice. These data suggest that FPZ antagonized the therapeutic efficacy of FLC but enhanced the antifungal activity of AmB in the treatment of candidiasis.


Assuntos
Anfotericina B/farmacologia , Antifúngicos/farmacologia , Antipsicóticos/farmacologia , Candida albicans/efeitos dos fármacos , Interações Medicamentosas , Fluconazol/farmacologia , Flufenazina/farmacologia , Anfotericina B/administração & dosagem , Estruturas Animais , Animais , Antifúngicos/administração & dosagem , Antipsicóticos/administração & dosagem , Candidíase/tratamento farmacológico , Contagem de Colônia Microbiana , Modelos Animais de Doenças , Fluconazol/administração & dosagem , Flufenazina/administração & dosagem , Perfilação da Expressão Gênica , Regulação Fúngica da Expressão Gênica/efeitos dos fármacos , Camundongos , Resultado do Tratamento
3.
Cochrane Database Syst Rev ; 5: CD011884, 2018 05 11.
Artigo em Inglês | MEDLINE | ID: mdl-29749607

RESUMO

BACKGROUND: Many people with schizophrenia do not respond to an initially prescribed antipsychotic drug. In such cases, one treatment strategy could be to increase the antipsychotic dose; and another strategy could be to switch to a different antipsychotic drug. OBJECTIVES: To examine the efficacy of increasing the antipsychotic dose versus switching the antipsychotic drug in the treatment of non-responsive people with schizophrenia. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (10 June 2014, 6 October 2015, and 30 March 2017). We examined references of all included studies for further trials. SELECTION CRITERIA: All relevant randomised controlled trials (RCTs) comparing increasing the antipsychotic dose versus switching to a different antipsychotic drug for people with schizophrenia who have not responded to their initial antipsychotic treatment. DATA COLLECTION AND ANALYSIS: At least two review authors independently extracted data. We analysed dichotomous data using relative risks (RR) and their 95% confidence intervals (CIs). We analysed continuous data using mean differences (MD) and their 95% CIs. We assessed risk of bias for included studies and used GRADE to create a 'Summary of findings' table. MAIN RESULTS: We include one RCT with relevant data on 29 participants in this review. The trial had a parallel design and was double-blind, but blinding procedures were not described. The trial included people who were non-responsive to fluphenazine 20 mg/day administered for 4 weeks. Participants were randomly assigned to continuing treatment with fluphenazine 20 mg/day, increasing the dose to fluphenazine 80 mg/day or switching to haloperidol 20 mg/day for four additional weeks. Data were reported only for 47 out of 58 initially randomised participants. The trial was published in 1993. The fact that only one RCT with a small sample size (N = 29) was included in the analysis limits the quality of the evidence. Overall, no clear difference was found between groups in terms of the three available outcomes: global state (number of participants with clinically relevant response (RR 1.63, 95% CI 0.17 to 15.99, very low quality evidence); general mental state (endpoint score, BPRS total) (MD 2.00, 95% CI -4.20 to 8.20, very low quality evidence); and negative symptoms (endpoint score, SANS) (MD 3.40, 95% CI -12.56 to 19.36). No data were reported for leaving the study early, adverse effects, time in hospital, quality of life, satisfaction with care and functioning. AUTHORS' CONCLUSIONS: There is extremely limited evidence and no clear conclusions can be drawn. There is an urgent need for further trials in order to determine the optimal treatment strategy for people with schizophrenia who do not respond to their initial antipsychotic treatment.


Assuntos
Antipsicóticos/administração & dosagem , Substituição de Medicamentos , Flufenazina/administração & dosagem , Haloperidol/administração & dosagem , Humanos , Esquizofrenia/tratamento farmacológico , Resultado do Tratamento
6.
Neurochem Res ; 42(11): 3033-3040, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28744755

RESUMO

Typical antipsychotics, which are commonly used to treat schizophrenia, cause motor disorders such as tardive dyskinesia (TD) in humans and orofacial dyskinesia (OD) in rodents. The disease mechanisms as well as treatment effectiveness are still unknown. In this study, we investigated the effect of resveratrol, a polyphenol with neuroprotective properties, on behavioral changes induced by chronic treatment with fluphenazine in rats and the possible relationship between monoamine oxidase (MAO) activity and vacuous chewing movements (VCMs). Rats were treated for 18 weeks with fluphenazine enantate [25 mg/kg, intramuscularly (i.m.), every 21 days] and/or resveratrol (20 mg/kg, offered daily in drinking water). Next, body weight gain, behavioral parameters (VCMs and open field tests-locomotor and rearing activity), and MAO activity were evaluated. Fluphenazine treatment reduced body weight gain, number of crossings and rearings, and the co-treatment with resveratrol did not affect these alterations. Fluphenazine increased the prevalence and intensity of VCMs and the co-treatment with resveratrol reduced the VCMs. Furthermore, a negative correlation was found between the number of VCMs and MAO-B activity in the striatum of rats. Our data suggest that resveratrol could be promissory to decrease OD. Moreover, MAO-B activity in the striatum seems to be related to VCMs intensity.


Assuntos
Antioxidantes/uso terapêutico , Antipsicóticos/toxicidade , Discinesias/prevenção & controle , Flufenazina/toxicidade , Atividade Motora/efeitos dos fármacos , Estilbenos/uso terapêutico , Animais , Antioxidantes/farmacologia , Antipsicóticos/administração & dosagem , Esquema de Medicação , Discinesias/psicologia , Flufenazina/administração & dosagem , Masculino , Mastigação/efeitos dos fármacos , Mastigação/fisiologia , Atividade Motora/fisiologia , Ratos , Ratos Wistar , Resveratrol , Estilbenos/farmacologia
7.
Cochrane Database Syst Rev ; (2): CD000307, 2015 Feb 05.
Artigo em Inglês | MEDLINE | ID: mdl-25654768

RESUMO

BACKGROUND: Intramuscular injections (depot preparations) offer an advantage over oral medication for treating schizophrenia by reducing poor compliance. The benefits gained by long-acting preparations, however, may be offset by a higher incidence of adverse effects. OBJECTIVES: To assess the effects of fluphenazine decanoate and enanthate versus oral anti-psychotics and other depot neuroleptic preparations for individuals with schizophrenia in terms of clinical, social and economic outcomes. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Trials Register (February 2011 and October 16, 2013), which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. SELECTION CRITERIA: We considered all relevant randomised controlled trials (RCTs) focusing on people with schizophrenia comparing fluphenazine decanoate or enanthate with placebo or oral anti-psychotics or other depot preparations. DATA COLLECTION AND ANALYSIS: We reliably selected, assessed the quality, and extracted data of the included studies. For dichotomous data, we estimated risk ratio (RR) with 95% confidence intervals (CI). Analysis was by intention-to-treat. We used the mean difference (MD) for normal continuous data. We excluded continuous data if loss to follow-up was greater than 50%. Tests of heterogeneity and for publication bias were undertaken. We used a fixed-effect model for all analyses unless there was high heterogeneity. For this update. we assessed risk of bias of included studies and used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to create a 'Summary of findings' table. MAIN RESULTS: This review now includes 73 randomised studies, with 4870 participants. Overall, the quality of the evidence is low to very low.Compared with placebo, use of fluphenazine decanoate does not result in any significant differences in death, nor does it reduce relapse over six months to one year, but one longer-term study found that relapse was significantly reduced in the fluphenazine arm (n = 54, 1 RCT, RR 0.35, CI 0.19 to 0.64, very low quality evidence). A very similar number of people left the medium-term studies (six months to one year) early in the fluphenazine decanoate (24%) and placebo (19%) groups, however, a two-year study significantly favoured fluphenazine decanoate (n = 54, 1 RCT, RR 0.47, CI 0.23 to 0.96, very low quality evidence). No significant differences were found in mental state measured on the Brief Psychiatric Rating Scale (BPRS) or in extrapyramidal adverse effects, although these outcomes were only reported in one small study each. No study comparing fluphenazine decanoate with placebo reported clinically significant changes in global state or hospital admissions.Fluphenazine decanoate does not reduce relapse more than oral neuroleptics in the medium term (n = 419, 6 RCTs, RR 1.46 CI 0.75 to 2.83, very low quality evidence). A small study found no difference in clinically significant changes in global state. No difference in the number of participants leaving the study early was found between fluphenazine decanoate (17%) and oral neuroleptics (18%), and no significant differences were found in mental state measured on the BPRS. Extrapyramidal adverse effects were significantly less for people receiving fluphenazine decanoate compared with oral neuroleptics (n = 259, 3 RCTs, RR 0.47 CI 0.24 to 0.91, very low quality evidence). No study comparing fluphenazine decanoate with oral neuroleptics reported death or hospital admissions.No significant difference in relapse rates in the medium term between fluphenazine decanoate and fluphenazine enanthate was found (n = 49, 1 RCT, RR 2.43, CI 0.71 to 8.32, very low quality evidence), immediate- and short-term studies were also equivocal. One small study reported the number of participants leaving the study early (29% versus 12%) and mental state measured on the BPRS and found no significant difference for either outcome. No significant difference was found in extrapyramidal adverse effects between fluphenazine decanoate and fluphenazine enanthate. No study comparing fluphenazine decanoate with fluphenazine enanthate reported death, clinically significant changes in global state or hospital admissions. AUTHORS' CONCLUSIONS: There are more data for fluphenazine decanoate than for the enanthate ester. Both are effective antipsychotic preparations. Fluphenazine decanoate produced fewer movement disorder effects than other oral antipsychotics but data were of low quality, and overall, adverse effect data were equivocal. In the context of trials, there is little advantage of these depots over oral medications in terms of compliance but this is unlikely to be applicable to everyday clinical practice.


Assuntos
Antipsicóticos/uso terapêutico , Flufenazina/análogos & derivados , Administração Oral , Antipsicóticos/administração & dosagem , Preparações de Ação Retardada/administração & dosagem , Preparações de Ação Retardada/uso terapêutico , Flufenazina/administração & dosagem , Flufenazina/uso terapêutico , Humanos , Injeções Intramusculares , Ensaios Clínicos Controlados Aleatórios como Assunto , Esquizofrenia/tratamento farmacológico
8.
J Anal Toxicol ; 37(8): 594-9, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23986099

RESUMO

Fluphenazine, a potent antipsychotic used to treat schizophrenia in humans, is used in racehorses as a performance-enhancing drug, and for that reason it has been banned by the Association of Racing Commissioners International. A liquid chromatography-tandem mass spectrometry method for detecting and quantitating fluphenazine in equine serum was developed and validated. The method was then employed to quantitate fluphenazine in serum samples collected from three study horses after intramuscular injection of fluphenazine decanoate. Stability testing showed that fluphenazine is stable in unextracted and processed samples as well as samples that have been subjected to up to three freeze-thaw cycles. The limit of detection and lower limit of quantitation of fluphenazine were determined to be 0.05 and 0.1 ng/mL, respectively. Precision was evaluated based on one-way analysis of variance of replicate quality control samples and was determined to be 27.2% at the 0.2 ng/mL level and 18.1% at the 2 ng/mL level. Bias was determined to be 0.55% at the 0.2 ng/mL level and 3.66% at the 2 ng/mL level. In two of three horses, fluphenazine was detected in serum up to 14 days post-administration. The highest detected concentration of fluphenazine in serum was 1.4 ng/mL.


Assuntos
Dopagem Esportivo/prevenção & controle , Flufenazina/análogos & derivados , Cavalos/sangue , Detecção do Abuso de Substâncias/veterinária , Animais , Cromatografia Líquida/métodos , Feminino , Flufenazina/administração & dosagem , Flufenazina/sangue , Limite de Detecção , Sensibilidade e Especificidade , Detecção do Abuso de Substâncias/métodos , Espectrometria de Massas em Tandem
9.
Vojnosanit Pregl ; 70(3): 267-73, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23607237

RESUMO

BACKGROUND/AIM: There is a high rate of schizophrenic patients who do not adhere to their prescribed therapy, despite the implementation of antipsychotic long-acting injections and the introduction of atypical antipsychotics. The aim of this study was to investigate the differences in sociodemographic, clinical and medication adherence variables between the two groups of schizophrenic patients on maintenance therapy with depot antipsychotic fluphenazine decanoate and oral antipsychotics only as well as a correlation between the medication adherence and other examined variables. METHODS: A total of 56 patients of both genders, aged < 60 years, with the diagnosis of schizophrenia (F20) (ICD-10, 1992) clinically stable for at least 6 months were introduced in this cross-sectional study. The patients from the depot group (n = 19) were on classical depot antipsychotic fluphenazine decanoate administering intramuscularly every 4 weeks (with or without oral antipsychotic augmentation) and the patients from the oral group (n = 37) were on oral therapy alone with classical or atypical antipsychotics, either as monotherapy or combined. The Positive and Negative Syndrome Scale (PANSS) was used to assess symptom severity. Item G12 of the PANSS was used to assess insight into the illness. The patients completed the Medical Adherence Rating Scale (MARS) was used to assess adherence to the therapy. A higher MARS score indicates behavior [Medical Adherence Questionnaire (MAQ subscale)] and attitudes toward medication [Drug Attitude Inventory (DAI subscale)] that are more consistent with treatment adherence. The exclusion criteria were determined. The Pearson's chi2 test was used to compare categorical variables, Student's t-test to compare continuous variables and Pearson's correlation to test the correlation significance; p = 0.05. RESULTS: Significant between-group differences in age, illness duration, chlorpromazine equivalents, PANSS score and DAI subscore were found. Item G12 of the PANSS subscore and MARS score correlated significantly negatively. A significant positive correlation between receiving depot antipsychotic and DAI subscore as well as between illness duration and both DAI subscore and MARS score were also found. CONCLUSION: Schizophrenic patients on classical depot antipsychotic maintenance therapy might present subpopulation of patients with significantly longer illness duration, more favorable medication attitude and outcome in relation to those on oral antipsychotics alone.


Assuntos
Antipsicóticos/administração & dosagem , Flufenazina/análogos & derivados , Adesão à Medicação , Esquizofrenia/tratamento farmacológico , Administração Oral , Adulto , Preparações de Ação Retardada , Feminino , Flufenazina/administração & dosagem , Humanos , Injeções Intramusculares , Masculino , Pessoa de Meia-Idade
10.
Eur J Pharmacol ; 702(1-3): 165-73, 2013 Feb 28.
Artigo em Inglês | MEDLINE | ID: mdl-23395964

RESUMO

Fluphenazine is a potent antipsychotic drug that can increase action potential duration and induce QT prolongation in several animal models and in humans. As the block of cardiac human ether-a-go-go-related gene (hERG) channels is one of the leading causes of acquired long QT syndrome, we investigated the acute effects of fluphenazine on hERG channels to determine the electrophysiological basis for its proarrhythmic potential. Fluphenazine at concentrations of 0.1-1.0 µM increased the action potential duration at 90% of repolarization (APD90) and action potential duration at 50% of repolarization (APD50) in 5 min when action potentials were elicited under current-clamp conditions in guinea pig ventricular myocytes. We examined the effects of fluphenazine on hERG channels expressed in Xenopus oocytes and HEK293 cells using two-microelectrode voltage-clamp and patch-clamp techniques. The IC50 for the fluphenazine-induced block of hERG currents in HEK293 cells at 36 °C was 0.102 µM at +20 mV. Fluphenazine-induced a concentration-dependent decrease of the current amplitude at the end of the voltage steps and hERG tail currents. The fluphenazine-dependent hERG block in Xenopus oocytes increased progressively relative to the degree of depolarization. Fluphenazine affected the channels in the activated and inactivated states but not in the closed states, and the S6 domain mutation from tyrosine to alanine at amino acid 652 (Y652A) attenuated the hERG current block. These results suggest that the antipsychotic drug fluphenazine is a potent blocker of hERG channels, providing a molecular mechanism for the drug-induced arrhythmogenic side effects.


Assuntos
Potenciais de Ação/efeitos dos fármacos , Antipsicóticos/administração & dosagem , Canais de Potássio Éter-A-Go-Go/antagonistas & inibidores , Flufenazina/administração & dosagem , Bloqueadores dos Canais de Potássio/administração & dosagem , Animais , Canais de Potássio Éter-A-Go-Go/fisiologia , Cobaias , Células HEK293 , Humanos , Simulação de Acoplamento Molecular , Miócitos Cardíacos/efeitos dos fármacos , Miócitos Cardíacos/fisiologia , Oócitos/efeitos dos fármacos , Oócitos/fisiologia , Xenopus laevis
11.
Eur J Pharmacol ; 693(1-3): 31-6, 2012 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-22926199

RESUMO

The aim of this study was to examine whether thioxanthine-type antipsychotics (chlorprothixene and cis(z)-flupenthixol) and phenothiazine-type antipsychotics (chlorpromazine and fluphenazine) produced spinal anesthesia. Using a rat model of intrathecal injection, we evaluated spinal anesthesia of antipsychotic drugs (chlorprothixene, cis(z)-flupenthixol, chlorpromazine, and fluphenazine) and bupivacaine, a known local anesthetic. At a same dose of 2.31 µmol/kg, chlorprothixene had the most potent spinal blockades (P<0.001) and the longest duration of action (P<0.001) of motor function and nociception among those antipsychotic drugs. On the 50% effective dose (ED(50)) basis, the ranks of potencies were chlorprothixene=bupivacaine>cis(z)-flupenthixol>chlorpromazine>fluphenazine (P<0.01 for the differences) in dose-response studies. At an equianesthetic basis (ED(25), ED(50), and ED(75)), the spinal block duration caused by chlorprothixene, cis(z)-flupenthixol, chlorpromazine or fluphenazine was longer than that caused by bupivacaine (P<0.05). These results showed that chlorprothixene produced a similar potency and longer duration of spinal anesthesia than did bupivacaine, whereas several other antipsychotics produced less potency than did bupivacaine.


Assuntos
Anestésicos/administração & dosagem , Clorpromazina/administração & dosagem , Clorprotixeno/administração & dosagem , Flupentixol/administração & dosagem , Flufenazina/administração & dosagem , Raquianestesia/métodos , Animais , Antipsicóticos/administração & dosagem , Comportamento Animal/efeitos dos fármacos , Antagonistas de Dopamina/administração & dosagem , Injeções Espinhais , Masculino , Nociceptividade/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Sensação/efeitos dos fármacos
12.
J Clin Psychiatry ; 73(5): 669-75, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22480442

RESUMO

OBJECTIVE: This multisite randomized trial addressed risks and benefits of staying on long-acting injectable haloperidol or fluphenazine versus switching to long-acting injectable risperidone microspheres. METHOD: From December 2004 through March 2008, adult outpatients with a Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition diagnosis of schizophrenia or schizoaffective disorder who were taking haloperidol decanoate (n = 40) or fluphenazine decanoate (n = 22) were randomly assigned to stay on current long-acting injectable medication or switch to risperidone microspheres and followed for 6 months under study protocol and an additional 6 months naturalistic follow-up. Kaplan-Meier and Cox regression analyses were used to examine the primary outcome (time to treatment discontinuation), and random regression models were used to examine secondary outcomes. RESULTS: Groups did not differ significantly in time to treatment discontinuation through 6 months of protocol-driven treatment. When the 6-month naturalistic follow-up period was included, time to treatment discontinuation was significantly shorter for individuals assigned to switch than for individuals assigned to stay (10% of stayers discontinued versus 31% of switchers; P = .01). Groups did not differ with respect to psychopathology, hospitalizations, sexual side effects, new-onset tardive dyskinesia, or new-onset extrapyramidal symptoms. However, those randomized to switch to long-acting injectable risperidone microspheres had greater increases in body mass (increase of 1.0 body mass index [BMI] versus decrease of -0.3 BMI; P = .00) and prolactin (maximum increase to 23.4 ng/mL versus decrease to 15.2 ng/mL, P = .01) compared to those randomized to stay. CONCLUSION: Switching from haloperidol decanoate or fluphenazine decanoate to risperidone microspheres resulted in more frequent treatment discontinuation as well as significant weight gain and increases in prolactin. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00044655.


Assuntos
Antipsicóticos/administração & dosagem , Substituição de Medicamentos , Flufenazina/administração & dosagem , Haloperidol/análogos & derivados , Microesferas , Risperidona/administração & dosagem , Esquizofrenia/tratamento farmacológico , Antipsicóticos/efeitos adversos , Connecticut , Preparações de Ação Retardada , Feminino , Flufenazina/efeitos adversos , Seguimentos , Haloperidol/administração & dosagem , Haloperidol/efeitos adversos , Humanos , Hiperprolactinemia/induzido quimicamente , Injeções , Análise de Intenção de Tratamento , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Cooperação do Paciente , Modelos de Riscos Proporcionais , Risperidona/efeitos adversos , Aumento de Peso
13.
Psychiatr Q ; 83(3): 335-41, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22271354

RESUMO

A number of innovative delivery systems for acute antipsychotic pharmacotherapy have been developed over the years which include oral suspensions, rapidly dissolving wafers and acute intramuscular preparations. Currently, the availability of first generation antipsychotic (FGA) formulations is limited to two high potency agents: haloperidol and fluphenazine. At Yale New-Haven Psychiatric Hospital, the hospital pharmacy was able to create perphenazine suspension, a mid-potency FGA, with a record of effectiveness and tolerability that was no worse than that of second generation antipsychotics (SGAs) in the CATIE trial. In this study we compare perphenazine suspension to other first and SGAs in the risk of extrapyramidal reactions and whether or not patients were continued on the same antipsychotic they were started with at the time of discharge. Medical records of patients who received acute pharmacotherapy in a unique form while hospitalized at Yale New Haven Psychiatric Hospital from July 2009 to December 2009 were examined. All data were collected thru a chart review using a form that was created to systematically document experiences. A total of 229 patients were included in the study. There were no significant differences between treatment groups on gender, age, race or diagnosis. In the entire samples 1.75% had pseudo-parkonisnism, 1.31% had acute dystonia, 0.04% had tardive dyskinesia, 1.31% akithesia, and 4.8% any neurological side effects. There were no significant differences between agents in the likelihood of any of these side effects or of having any side effect. Higher use of anticholinergics was found in patients treated with FGAs. We also found that 77% were discharged on the same antipsychotic agent they received when they were initially hospitalized. A wide range of acute oral pharmacoptherapy in non-tablet formulations of first and SGAs should be available in psychiatric hospital formularies. FGAs seems to be as well tolerated as SGAs.


Assuntos
Antipsicóticos/administração & dosagem , Antagonistas Colinérgicos/uso terapêutico , Sistemas de Liberação de Medicamentos , Hospitais Psiquiátricos , Transtornos dos Movimentos/epidemiologia , Perfenazina/administração & dosagem , Adulto , Antipsicóticos/efeitos adversos , Benzodiazepinas/administração & dosagem , Benzodiazepinas/efeitos adversos , Ensaios Clínicos como Assunto , Composição de Medicamentos , Feminino , Flufenazina/administração & dosagem , Flufenazina/efeitos adversos , Haloperidol/administração & dosagem , Haloperidol/efeitos adversos , Humanos , Masculino , Transtornos dos Movimentos/etiologia , Olanzapina , Alta do Paciente , Perfenazina/efeitos adversos , Risperidona/administração & dosagem , Risperidona/efeitos adversos , Suspensões , Resultado do Tratamento
14.
Pharmacol Biochem Behav ; 101(2): 307-10, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22266770

RESUMO

Treatment with classical neuroleptics in humans can produce a serious side effect, known as tardive dyskinesia (TD). Here, we examined the possible neuroprotective effects of resveratrol, a polyphenol compound contained in red grapes and red wine, in an animal model of orofacial dyskinesia (OD) induced by acute treatment with fluphenazine. Adult male rats were treated during 3 weeks with fluphenazine enantate (25 mg/kg, i.m., single administration) and/or resveratrol (1 mg/kg, s.c., 3 times a week). Vacuous chewing movements (VCMs), locomotor and exploratory performance were evaluated. Fluphenazine treatment produced VCM in 70% of rats and the concomitant treatment with resveratrol decreased the prevalence to 30%, but did not modify the intensity of VCMs. Furthermore, the fluphenazine administration reduced the locomotor and exploratory activity of animals in the open field test. Resveratrol co-treatment was able to protect the reduction of both parameters. Taken together, our data suggest that resveratrol could be considered a potential neuroprotective agent by reducing motor disorders induced by fluphenazine treatment.


Assuntos
Flufenazina/toxicidade , Mastigação/efeitos dos fármacos , Transtornos dos Movimentos/prevenção & controle , Fármacos Neuroprotetores/uso terapêutico , Estilbenos/uso terapêutico , Animais , Flufenazina/administração & dosagem , Flufenazina/antagonistas & inibidores , Masculino , Transtornos dos Movimentos/fisiopatologia , Fármacos Neuroprotetores/farmacologia , Ratos , Ratos Wistar , Resveratrol , Estilbenos/farmacologia
15.
Gen Hosp Psychiatry ; 33(1): 84.e5-7, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21353143

RESUMO

We present the case of a woman with paranoid schizophrenia who was receiving oral risperidone. She developed neuroleptic malignant syndrome (NMS) following the addition of depot fluphenazine for the treatment of refractory delusions. NMS subsided and psychotic features were controlled after both antipsychotics were discontinued and the patient was treated instead with olanzapine.


Assuntos
Antipsicóticos/efeitos adversos , Flufenazina/análogos & derivados , Síndrome Maligna Neuroléptica/etiologia , Risperidona/efeitos adversos , Adulto , Antipsicóticos/administração & dosagem , Antipsicóticos/uso terapêutico , Delusões/tratamento farmacológico , Feminino , Flufenazina/administração & dosagem , Flufenazina/efeitos adversos , Flufenazina/uso terapêutico , Humanos , Risperidona/administração & dosagem , Risperidona/uso terapêutico , Esquizofrenia Paranoide/tratamento farmacológico
16.
Trop Doct ; 40(4): 247-8, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-20826590

RESUMO

Psychiatric illnesses are a significant cause of morbidity all over the world. In India many people with mental disorders are unable to access psychiatric care for a variety of reasons. This article describes the successful management of a person with schizophrenia in the community through a primary care team in liaison with psychiatrist services.


Assuntos
Antipsicóticos/administração & dosagem , Flufenazina/análogos & derivados , Acessibilidade aos Serviços de Saúde , Esquizofrenia/tratamento farmacológico , Serviços Comunitários de Saúde Mental , Feminino , Flufenazina/administração & dosagem , Comportamentos Relacionados com a Saúde , Humanos , Índia , Equipe de Assistência ao Paciente , Atenção Primária à Saúde , Esquizofrenia/diagnóstico , Esquizofrenia/reabilitação , Resultado do Tratamento , Adulto Jovem
17.
Schizophr Res ; 119(1-3): 153-9, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20347267

RESUMO

BACKGROUND: This study aimed to characterize the inpatient utilization of depot antipsychotics. METHOD: The characteristics of adults with schizophrenia or schizoaffective disorder, hospitalized for at least 28 days, and who were prescribed depot antipsychotics were examined from 2004 to 2006 using a database from a large state-operated psychiatric hospital system. Demographic and clinical characteristics of patients receiving depot fluphenazine or haloperidol were compared to those prescribed depot risperidone. RESULTS: We identified 2210 unique patients who initiated treatment with a depot antipsychotic (after receiving oral antipsychotics). Of these, 1484 (67.1%) received depot fluphenazine or haloperidol, and 726 (32.9%) received risperidone as their initial depot antipsychotic. Patients who received depot risperidone did not differ from those receiving depot fluphenazine or haloperidol with regard to demographics, diagnosis of schizoaffective disorder, number of comorbid psychiatric or medical diagnoses, or diagnosis of substance abuse. Patients started on depot risperidone during the observation period had a longer length of stay prior to initiation of depot than those started on depot fluphenazine or haloperidol (583 days vs. 237 days, t=5.489, p<.001). Patients who started on depot risperidone were less likely to be discharged on that medication than were patients who started on depot fluphenazine or haloperidol (odds ratio from Cox regression model=0.846 [95% CI 0.745-0.960]). CONCLUSIONS: Patients initiated on depot risperidone had a longer length of stay prior to their first injection and were less likely to be discharged on that medication compared to patients initiated on depot fluphenazine or haloperidol, possibly indicating that patients initiating depot risperidone had a more severe or treatment-resistant course of illness and/or that there were reimbursement barriers for the outpatient utilization of depot risperidone, or that efficacy differences exist between the depot antipsychotics at the doses used in this population.


Assuntos
Antipsicóticos/administração & dosagem , Flufenazina/análogos & derivados , Haloperidol/análogos & derivados , Transtornos Psicóticos/tratamento farmacológico , Risperidona/administração & dosagem , Esquizofrenia/tratamento farmacológico , Psicologia do Esquizofrênico , Administração Oral , Adulto , Antipsicóticos/efeitos adversos , Preparações de Ação Retardada , Relação Dose-Resposta a Droga , Esquema de Medicação , Quimioterapia Combinada , Uso de Medicamentos , Feminino , Flufenazina/administração & dosagem , Flufenazina/efeitos adversos , Haloperidol/administração & dosagem , Haloperidol/efeitos adversos , Humanos , Injeções Intramusculares , Estimativa de Kaplan-Meier , Tempo de Internação , Masculino , Microesferas , Pessoa de Meia-Idade , Alta do Paciente/estatística & dados numéricos , Modelos de Riscos Proporcionais , Transtornos Psicóticos/psicologia , Risperidona/efeitos adversos , Esquizofrenia/diagnóstico , Resultado do Tratamento
18.
Basic Clin Pharmacol Toxicol ; 105(1): 51-7, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19486337

RESUMO

The aim of this study was to assess the toxic effects of chronic exposure to fluphenazine in liver and kidney of rats, as well as the possible protective effect of diphenyl diselenide on the fluphenazine-induced damage. Long-term treatment with fluphenazine caused an increase in lipid peroxidation levels in liver and kidney homogenates. Diphenyl diselenide treatment did not affect delta-aminolevulinate dehydratase (delta-ALA-D) activity, but fluphenazine alone or in combination with diphenyl diselenide showed an inhibitory effect on delta-ALA-D activity in liver. Diphenyl diselenide plus fluphenazine treatment increased the reactivation index of hepatic delta-ALA-D by approximately 80%. Superoxide dismutase activity decreased in liver of rats treated with fluphenazine alone. The combined treatment with fluphenazine and diphenyl diselenide was able to ameliorate superoxide dismutase activity in liver of rats. Catalase activity was augmented in liver from rats treated with fluphenazine, and this increase was prevented when diphenyl diselenide was co-administered. Taken together, these results indicate that the association of diphenyl diselenide with fluphenazine could protect the liver from lipid peroxidation and ameliorate superoxide dismutase and catalase activities. Moreover, our data point to the relationship between the oxidative stress and fluphenazine treatment in liver and kidney of rats.


Assuntos
Antioxidantes/farmacologia , Antipsicóticos/toxicidade , Derivados de Benzeno/farmacologia , Flufenazina/toxicidade , Rim/efeitos dos fármacos , Fígado/efeitos dos fármacos , Compostos Organosselênicos/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Substâncias Protetoras/farmacologia , Animais , Antipsicóticos/administração & dosagem , Biomarcadores , Catalase/metabolismo , Ativação Enzimática , Flufenazina/administração & dosagem , Injeções Intramusculares , Injeções Subcutâneas , Rim/química , Rim/enzimologia , Peroxidação de Lipídeos/efeitos dos fármacos , Fígado/química , Fígado/enzimologia , Masculino , Estresse Oxidativo/fisiologia , Sintase do Porfobilinogênio/metabolismo , Ratos , Ratos Wistar , Superóxido Dismutase/metabolismo , Substâncias Reativas com Ácido Tiobarbitúrico , Testes de Toxicidade Crônica
19.
Psychiatr Danub ; 20(1): 42-52, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18376330

RESUMO

AIM: To compare patient's attitudes, demographic, clinical characteristics, psychopathology, insight and type of antipsychotic therapy in compliant and non-compliant outpatients with schizophrenia; to explore correlations between patient's attitudes and related variables. METHODS: A sample of 44 outpatients of both genders (> 60 years), with a diagnosis of ICD-10 Schizophrenia (F20) was included into the study. All the patients were on maintenance treatment with different classes of antipsychotics (oral, depot or both), for at least 6 months from the latest hospitalisation. The exclusion criteria were determined. The BPRS and the PANSS were used to assess psychopathology and insight (G12 item). The self-report questionnaire MARS was used to assess patient's attitudes. RESULTS: Compliant patients (N=37) showed the following significant differences compared to non-compliant patients (N=7): higher the MARS (p<0.001), lower the PANSS (Positive sub score) (p<0.01) G12 scores (p<0.01) (the Student t test) and percentage of patients with previous non-compliance (p<0.05) (chi2 test). Considerable correlation between the MARS and the BPRS (p<0.001), the PANSS (Positive, General psychopathology) (p<0.001; p<0.01), G12 scores (p<0.05) (negative) and current compliance (p<0.001) was also found (The Spearman's correlation). CONCLUSIONS: Our results suggest that special attention should be paid to attitudes, severity of psychopathology, insight and history of non-compliance in compliance evaluation of outpatients with schizophrenia.


Assuntos
Antipsicóticos/administração & dosagem , Conhecimentos, Atitudes e Prática em Saúde , Cooperação do Paciente/psicologia , Esquizofrenia/tratamento farmacológico , Psicologia do Esquizofrênico , Administração Oral , Adulto , Fatores Etários , Assistência Ambulatorial , Antipsicóticos/efeitos adversos , Clozapina/administração & dosagem , Clozapina/efeitos adversos , Estudos Transversais , Preparações de Ação Retardada , Feminino , Flufenazina/administração & dosagem , Flufenazina/efeitos adversos , Flufenazina/análogos & derivados , Haloperidol/administração & dosagem , Haloperidol/efeitos adversos , Humanos , Assistência de Longa Duração , Masculino , Pessoa de Meia-Idade , Escalas de Graduação Psiquiátrica , Risperidona/administração & dosagem , Risperidona/efeitos adversos , Iugoslávia
20.
Psychiatr Serv ; 59(3): 315-7, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18308914

RESUMO

OBJECTIVE: This study compared the time to discontinuation for any reason of first-generation antipsychotics--in oral versus depot formulation--in the usual care of schizophrenia. METHODS: This study used data from a three-year, prospective, nonrandomized, noninterventional, multisite study of schizophrenia. Participants initiated on oral haloperidol or fluphenazine (N=202) were compared with those initiated on haloperidol or fluphenazine in depot formulation (N=97) on time to all-cause discontinuation for one year after initiation, by using Kaplan-Meier survival analysis, a Cox proportional hazards regression model, and propensity score-adjusted bootstrap resampling methods. RESULTS: Compared with participants treated with the oral formulation, those treated with depot first-generation antipsychotics had a significantly longer mean time to all-cause medication discontinuation and were twice as likely to stay on the medication. CONCLUSION: In the usual care of schizophrenia, treatment with first-generation antipsychotics in depot formulation appears to be associated with longer time to all-cause medication discontinuation compared with oral formulation of the same medication.


Assuntos
Antipsicóticos/uso terapêutico , Flufenazina/uso terapêutico , Haloperidol/uso terapêutico , Esquizofrenia/tratamento farmacológico , Administração Oral , Antipsicóticos/administração & dosagem , Preparações de Ação Retardada/administração & dosagem , Preparações de Ação Retardada/uso terapêutico , Manual Diagnóstico e Estatístico de Transtornos Mentais , Esquema de Medicação , Flufenazina/administração & dosagem , Haloperidol/administração & dosagem , Humanos , Estimativa de Kaplan-Meier , Estudos Prospectivos , Esquizofrenia/diagnóstico , Esquizofrenia/epidemiologia , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA